Form 8-K

8-K — Microbot Medical Inc.

Accession: 0001493152-26-019775

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000883975

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000883975

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 30, 2026

MICROBOT

MEDICAL INC.

(Exact

name of registrant as specified in its charter)

Delaware

000-19871

94-3078125

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

175

Derby St., Bld. 27

Hingham,

MA 02043

(Address

of Principal Executive Offices) (Zip Code)

Registrant’s

telephone number, including area code: (781) 875-3605

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.01 par value

MBOT

NASDAQ

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

Growth Company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

April 30, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it is continuing to implement

its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe, the Middle East, and Asia (“EMEA”).

The Company will continue to prioritize its commercial efforts in the U.S. market, while establishing regulatory, operational, and

commercial core capabilities required to enter international markets. The Company’s approach for commercial readiness in EMEA

will leverage the successful commercial launch of the Company’s LIBERTY® Endovascular Robotic System to

expand into key international markets. In this capacity, Mr. Tamir will lead the development and execution of a comprehensive EMEA sales

strategy, including go-to-market strategies, distribution and strategic partnerships, new product launches tailored to the market

needs, and regulatory requirements across the region.

The

press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information

in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18

of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be

deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

99.1

Press Release

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

MICROBOT

MEDICAL INC.

By:

/s/

Harel Gadot

Name:

Harel

Gadot

Title:

Chief

Executive Officer, President and Chairman

Date:

April 30, 2026

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Microbot

Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial

Readiness in Europe, the Middle East, and Asia (EMEA)

Commencement

of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent

Full Market Release in the U.S.

Strong

physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S.

supports commercial readiness throughout heavily populated regions

HINGHAM,

Mass., April 30, 2026 -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular

Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe,

the Middle East and Asia (EMEA). The Company will continue to prioritize its commercial efforts in the U.S. market, while establishing

regulatory, operational, and commercial core capabilities required to enter international markets. The Company’s approach for

EMEA will leverage the successful commercial launch of the LIBERTY system to expand into key international markets,

either by utilizing its FDA clearance or through the CE mark, which is expected by the end of this year. In this capacity, Mr. Tamir

will lead the development and execution of a comprehensive EMEA sales strategy, including go-to-market strategies, distribution, and

strategic partnerships, new product launches tailored to market needs, and regulatory requirements across the region.

Mr. Tamir brings over two decades of experience in

medical technology, with a successful track record of translating strategic vision into measurable impact. The EMEA region represents

a significant growth opportunity. The Company believes Europe alone represents a peripheral endovascular procedure volume comparable

to that of the United States, at approximately 2.3 million procedures, underscoring a significant opportunity for expansion

beyond the U.S. market.

The Company received U.S. Food and Drug Administration

(FDA) clearance for its technology in September 2025 and remains on track with its MDR process, with the anticipation of receiving

a CE mark approval by the end of 2026. The Company also plans to pursue opportunities in countries where it can leverage

its FDA clearance, which may help accelerate international expansion.

“Endovascular robotics is at an inflection

point, and LIBERTY is leading that transformation,” commented Alon Tamir, Vice President of Sales, Europe, the Middle East and

Asia (EMEA). “With over two decades of experience across the diagnostic, interventional, and robotics space, I’ve rarely

seen a technology so well positioned — FDA-cleared, already commercially launched, and now advancing toward CE mark approval. The

opportunity in EMEA is substantial, and I am committed to ensuring we capture it with the same discipline and execution that defined

the U.S. launch.”

“As we continue to focus on the U.S. market,

and build on the growing adoption of the LIBERTY System, especially after entering the Full Market Release phase, it is equally

important that we establish a robust commercial readiness strategy in certain international markets, applying the same disciplined

approach that supported our successful execution ahead of commencing commercialization in the U.S.,” commented Harel Gadot,

Chairman, CEO and President. “Alon’s addition strengthens our ability to expand our presence in key markets outside

the U.S. and advance key distribution and strategic partnerships, leveraging local expertise to ensure a well-coordinated

commercial strategy ahead of regulatory approval in these markets.”

About

Microbot Medical

Microbot

Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced

robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic

solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation,

Microbot is driving the future of endovascular care.

Learn

more at www.microbotmedical.com and connect on LinkedIn and X.

Safe

Harbor

Statements

to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development,

commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future

expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including,

but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,”

“intends,” “may,” “might,” “possible,” “potential,” “predicts,”

“projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,”

“expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but

the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,

including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular

Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory

pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes

in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from

new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual

property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors”

in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s

web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements,

except as required by law.

Contacts:

IR@microbotmedical.com

Media@microbotmedical.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (5096 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 19

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

000-19871

Entity Registrant Name

MICROBOT

MEDICAL INC.

Entity Central Index Key

0000883975

Entity Tax Identification Number

94-3078125

Entity Incorporation, State or Country Code

Entity Address, Address Line One

175

Derby St.

Entity Address, Address Line Two

Bld. 27

Entity Address, City or Town

Hingham

Entity Address, State or Province

Entity Address, Postal Zip Code

02043

City Area Code

(781)

Local Phone Number

875-3605

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.01 par value

Trading Symbol

MBOT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration